BR0307337A - Tratamento de disfunção sexual masculina - Google Patents

Tratamento de disfunção sexual masculina

Info

Publication number
BR0307337A
BR0307337A BR0307337-8A BR0307337A BR0307337A BR 0307337 A BR0307337 A BR 0307337A BR 0307337 A BR0307337 A BR 0307337A BR 0307337 A BR0307337 A BR 0307337A
Authority
BR
Brazil
Prior art keywords
treatment
sexual dysfunction
male sexual
male
oxytocin antagonist
Prior art date
Application number
BR0307337-8A
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Rachel Jane Russell
Stephen Derek Albert Street
Kim-Wah Tang
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0307337A publication Critical patent/BR0307337A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"TRATAMENTO DE DISFUNçãO SEXUAL MASCULINA". A presente invenção refere-se a uma composição compreendendo um antagonista seletivo de oxitocina para usar no tratamento e/ou prevenção de um distúrbio ejaculatório masculino; este antagonista seletivo da oxitocina sendo opcionalmente misturado com um veículo, diluente ou excipiente farmaceuticamente aceitável.
BR0307337-8A 2002-01-31 2003-01-20 Tratamento de disfunção sexual masculina BR0307337A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0202282.0A GB0202282D0 (en) 2002-01-31 2002-01-31 Treatment of male sexual dysfunction
PCT/IB2003/000140 WO2003064402A1 (en) 2002-01-31 2003-01-20 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
BR0307337A true BR0307337A (pt) 2004-12-07

Family

ID=9930155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307337-8A BR0307337A (pt) 2002-01-31 2003-01-20 Tratamento de disfunção sexual masculina

Country Status (16)

Country Link
EP (1) EP1470115A1 (pt)
JP (3) JP2005525321A (pt)
KR (2) KR100829262B1 (pt)
CN (1) CN100500658C (pt)
AU (1) AU2003201471B2 (pt)
BR (1) BR0307337A (pt)
CA (1) CA2474590A1 (pt)
GB (1) GB0202282D0 (pt)
HK (1) HK1073109A1 (pt)
IL (2) IL162822A0 (pt)
MX (1) MXPA04007434A (pt)
NZ (1) NZ546408A (pt)
PL (1) PL371415A1 (pt)
TW (1) TW200302732A (pt)
WO (1) WO2003064402A1 (pt)
ZA (1) ZA200405208B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3646871A1 (en) * 2018-10-30 2020-05-06 SEROJAC PME Handels GmbH Treatment and prevention of premature ejaculation (pe)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
EP0679084A1 (en) * 1992-12-23 1995-11-02 Merck & Co. Inc. Hydantoin and succinimide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists
US5693805A (en) * 1993-03-12 1997-12-02 Merck & Co., Inc. Process to derivatives of piperizinylcamphorsulfonyl oxytocin antagonists
GB0007884D0 (en) 2000-03-31 2000-05-17 Pfizer Ltd Diphenyl ether compounds useful in therapy
US20020028799A1 (en) * 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
ZA200405208B (en) 2005-08-31
JP2010209075A (ja) 2010-09-24
GB0202282D0 (en) 2002-03-20
NZ546408A (en) 2007-10-26
JP2005525321A (ja) 2005-08-25
CN1625553A (zh) 2005-06-08
CA2474590A1 (en) 2003-08-07
KR100829262B1 (ko) 2008-05-13
IL162822A0 (en) 2005-11-20
WO2003064402A1 (en) 2003-08-07
PL371415A1 (en) 2005-06-13
MXPA04007434A (es) 2004-10-11
KR20080011232A (ko) 2008-01-31
CN100500658C (zh) 2009-06-17
KR20040079958A (ko) 2004-09-16
AU2003201471B2 (en) 2009-03-26
EP1470115A1 (en) 2004-10-27
TW200302732A (en) 2003-08-16
JP2013151511A (ja) 2013-08-08
HK1073109A1 (en) 2005-09-23
IL162822A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
CY1112478T1 (el) Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
CY1114445T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για χρηση στη θεραπευτικη αγωγη ή προληψη αυτοανοσων ασθενειων
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
TW200505454A (en) Heteroaryl-fused pyrimidinyl compounds as anticancer agents
IL169439A0 (en) Fluoroalkoxy-substituted 1,3 - dihydro-isoindolyl compounds and their pharmaceutical uses
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
TNSN07240A1 (en) Compounds for flaviviridae treatment
TW200509896A (en) Analeptic and drug combinations
MY137620A (en) Therapeutic treatment
DE60233350D1 (de) IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES
EP1503748A4 (en) DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY
UA91988C2 (ru) Фармацевтическая композиция на основе антагонистов nk2 для применения в педиатрии
BR0307337A (pt) Tratamento de disfunção sexual masculina
MX2009005125A (es) Pirrolo[1,2-a]imidazoldiona efectiva en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos.
DE60236927D1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
GEP20115184B (en) Pharmacokinetically improved compounds
PT1355650E (pt) Combinacao de ingredientes activos contendo alfuzosina e apomorfina
CL2004001071A1 (es) Composicion farmaceutica que comprende modafinilo, un farmaco antineoplasico y un vehiculo farmaceuticamente aceptable.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A,8A E 9A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES.